SCHEMBL24913071

SCHEMBL24913071

Cc1ccc(C(C)S)c(C(=O)O)n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GRM5 P41594 2/20 0.33
PIN1 Q13526 1/20 0.33
KDM4E B2RXH2 2/20 0.33
HSD17B10 Q99714 2/20 0.33
USP2 O75604 1/20 0.33
HPGD P15428 1/20 0.33
ACE2 Q9BYF1 1/20 0.32
LMNA P02545 2/20 0.32
MEN1 O00255 4/20 0.31
KMT2A Q03164 4/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
SORT1 Q99523 1/20 0.31
ABCC4 O15439 1/20 0.31
PKM P14618 1/20 0.31
PTGS1 P23219 1/20 0.31
RAB9A P51151 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24679023 0.85 EIF4A3 (0.37) ALDH1A1MAPTSMN1; SMN2GRM5PIN1
SCHEMBL20209381 0.73 SMN1; SMN2 (0.39) ALDH1A1MAPTSMN1; SMN2GRM5PIN1
SCHEMBL2373944 0.72 ALDH1A1 (0.41) ALDH1A1MAPTSMN1; SMN2GRM5PIN1
SCHEMBL20992901 0.72 CCR1 (0.37) KDM4EHSD17B10USP2HPGDRAB9A
SCHEMBL25457031 0.71 P2RX7 (0.32)
SCHEMBL1759159 0.71 GRM5 (0.53) ALDH1A1MAPTSMN1; SMN2GRM5PIN1
SCHEMBL262422 0.71 GABRP (0.47) ALDH1A1MAPTSMN1; SMN2KDM4EUSP2
SCHEMBL29625359 0.71 GABRP (0.47) ALDH1A1MAPTSMN1; SMN2KDM4EUSP2
SCHEMBL2475355 0.70 KMT2A (0.41) ALDH1A1KDM4EKMT2A
SCHEMBL1405829 0.69 GRM5 (0.40) ALDH1A1MAPTSMN1; SMN2GRM5PIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873295-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PETRA PHARMA CORPORATION (US) 2024-01-16 US disclosed
US-20230017140-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE LOXO ONCOLOGY, INC. 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873295-B2 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of disease PIK3CA, PIK3R4, PIK3R5 ALDH1A1 3412/4885MAPT 3441/4885SMN1; SMN2 1813/4885
US-20230017140-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 ALDH1A1 3412/4885MAPT 3441/4885SMN1; SMN2 1813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.